Chauveinc L, Sola-Martinez M T, Martin-Duverneuil M, Mazeron J J, Faillot T, Cornu P, Capelle L, Delattre J Y, Poisson M, Baillet F, Chiras J
Hôpital de la Pitié, Salpétrière, France.
J Neurooncol. 1996 Feb;27(2):141-7. doi: 10.1007/BF00177477.
For the non-operable malignant glioma patients, prognosis remains poor, with a survival of 8 months for the glioblastomas (G), and 15 months for anaplastic astrocytomas (AA). 27 histologic proven malignant gliomas (17 AA and 10 G) were treated between April 1991 and June 1992. Median age was 48 years. The therapeutic protocol consisted of three courses of intra arterial chemotherapy (IAC) with ACNU, at intervals of six weeks, and a localised 60 Gy radiotherapy between the first and the second IAC course. 72 courses of IAC were delivered (2.4 per patient). Response rate was 51.8%. Median survival (MS) was 13 months, with a survival rate of 28% at 24 months. For the AA, MS was 21 months, with a survival rate of 37% at 24 months. For the G, median survival was 10 months. Responders were 65% for AA, 30% for G. Non responders all died before 24 months had relapsed with a MS of 9 months. 54% of responding patients had a 2 years survival. Toxicity were acceptable with 7% of haematological toxicity and partial loss of visual acuity in 11% of the case. No chronic neurological sequellae were noted. We compare theses results with two previous trials, concerning inoperable patients, treated by association of radiotherapy and systemic chemotherapy. Survival seems to be equivalent with HeCNU and with this treatment, but toxicity decrease with ACNU. Early radiotherapy does not increase complications. This treatment can be used for patients with inoperable malignant gliomas.
对于无法进行手术的恶性胶质瘤患者,预后仍然很差,胶质母细胞瘤(G)的生存期为8个月,间变性星形细胞瘤(AA)为15个月。1991年4月至1992年6月期间,对27例经组织学证实的恶性胶质瘤(17例AA和10例G)进行了治疗。中位年龄为48岁。治疗方案包括三个疗程的动脉内化疗(IAC),使用阿糖胞苷,间隔六周,以及在第一个和第二个IAC疗程之间进行局部60 Gy放疗。共进行了72个疗程的IAC(每位患者2.4个疗程)。缓解率为51.8%。中位生存期(MS)为13个月,24个月时的生存率为28%。对于AA,MS为21个月,24个月时的生存率为37%。对于G,中位生存期为10个月。AA的缓解者为65%,G为30%。未缓解者均在24个月前死亡,复发时的MS为9个月。54%的缓解患者存活了2年。毒性反应可以接受,血液学毒性为7%,11%的病例出现部分视力丧失。未发现慢性神经后遗症。我们将这些结果与之前两项关于无法手术患者的试验进行了比较,这两项试验采用了放疗和全身化疗联合治疗。使用环己亚硝脲和这种治疗方法时,生存期似乎相当,但使用阿糖胞苷时毒性降低。早期放疗不会增加并发症。这种治疗方法可用于无法进行手术的恶性胶质瘤患者。